Fatty acid synthase (FAS), a key enzyme in lipogenesis, has been identified as a potential therapeutic target for obesity due to its role in adipocyte differentiation and lipid accumulation. Here, FASN is linked to obesity due to melanocortin 4 receptor deficiency.